ArticleCell2016
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
Open access · greenAbstract read
In one paragraph
Article in Cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed
13.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 242 citations in OpenAlex.
- Trial
- Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.Blood advances · 2020Trial
- Comparative Analysis of the Clinicopathological Features of Follicular Lymphoma With and Without EZH2 Y646 Mutation.Pathology international · 2026Article
- Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors.Cancer genetics · 2026Article
- MutantFrontiers in immunology · 2026Article
- miR-155 aberrant expression impairs tumor rejection because of its targeting of ICOSL and multiple pathways implicated in the antitumor response.Pharmacological reviews · 2026Review
- A multi-omics integrative analyses revealsFrontiers in pharmacology · 2026Article
- Nodal Marginal Zone Lymphoma with Prominent Expansion of PD-1+ T-Follicular Helper Cells: A Persistent Diagnostic Challenge with a Heterogeneous Mutational Architecture.International journal of molecular sciences · 2025Article
- The Current Landscape of Modular CAR T Cells.International journal of molecular sciences · 2025Review
- Review
- IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma.Blood cancer discovery · 2025Article
- Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.Blood · 2025Review
- Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses.Leukemia · 2025Article
- Antibacterial Activity of the p53 Tumor Suppressor Protein-How Strong Is the Evidence?International journal of molecular sciences · 2025Review
- STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma.Leukemia · 2025Article
- Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.Cancers · 2025Review
- Early Onset Colorectal Cancer: Molecular Underpinnings Accelerating Occurrence.Cellular and molecular gastroenterology and hepatology · 2025Review
- Lymphoid stroma in all its states.Frontiers in immunology · 2025Review
- Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.Cancer research communications · 2024Article
- Pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma: additional evidence to support they are a single disease with variation in the histologic spectrum.Virchows Archiv : an international journal of pathology · 2024Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 11 institutions in 4 countries.
Michael BoiceCancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA.
Darin SalloumCancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Frederic MourcinINSERM U917, Equipe labellisée Ligue contre le Cancer, Université Rennes 1, EFS Bretagne, CHU Rennes, 35000 Rennes, France.
Viraj SanghviCancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Rada AminINSERM U917, Equipe labellisée Ligue contre le Cancer, Université Rennes 1, EFS Bretagne, CHU Rennes, 35000 Rennes, France.
Elisa OricchioSwiss Institute for Cancer Research (ISREC), EPFL SV-Batiment 19, 1003 Lausanne, Switzerland.
Man JiangCancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Anja MottokCentre for Lymphoid Cancer, British Columbia Cancer Agency and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V5Z 1L3, Canada.
Nicolas Denis-LagacheCentre National de la Recherche Scientifque, UMR 7276, Université de Limoges, 8700 Limoges, France.
Giovanni CirielloDepartment of Computational Biology, University of Lausanne, Rue du Bugnon 27, 1005 Lausanne, Switzerland; The Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
Wayne TamDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical School, New York, NY 10065, USA.
Julie Teruya-FeldsteinDepartment of Pathology, Mount Sinai Health System, New York, NY 10029, USA.
Elisa de StanchinaAntitumor Assessment Core Facility and Molecular Pharmacology Department, Memorial-Sloan Kettering Cancer Center, New York, NY 10065, USA.
Wing C ChanDepartment of Pathology, City of Hope, Duarte, CA 91010, USA.
Sami N MalekDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Daisuke EnnishiCentre for Lymphoid Cancer, British Columbia Cancer Agency and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V5Z 1L3, Canada.
Renier J BrentjensDepartment of Medicine, Memorial-Sloan Kettering Cancer Center, New York, NY 10065, USA.
Randy D GascoyneCentre for Lymphoid Cancer, British Columbia Cancer Agency and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V5Z 1L3, Canada.
Michel CognéCentre National de la Recherche Scientifque, UMR 7276, Université de Limoges, 8700 Limoges, France.
Karin TarteINSERM U917, Equipe labellisée Ligue contre le Cancer, Université Rennes 1, EFS Bretagne, CHU Rennes, 35000 Rennes, France. Electronic address: karin.tarte@univ-rennes1.fr.
Hans-Guido WendelCancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. Electronic address: wendelh@mskcc.org.
Memorial Sloan Kettering Cancer Center · USInserm · FRBC Cancer Agency · CACornell University · USUniversité de Limoges · FRCity of Hope · USÉcole Polytechnique Fédérale de Lausanne · CHMount Sinai Health System · USSIB Swiss Institute of Bioinformatics · CHUniversity of British Columbia · CAUniversity of Michigan · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTUMORICIDAL FUNCTIONS OF T LYMPHOCYTES IN PSMA TUMORSP01CA059350 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI O'REILLY, RICHARD JOHN · 1992 to 2012
$21.4MYNG1 PHD BINDING TO H3 3METHYL AT K4 PROMOTES TRANSCRIPTION AT TARGETED ORFSP41RR000862 · NCRR · ROCKEFELLER UNIVERSITY · PI DARNELL, JAMES E · 1985 to 2011
$16.1MTranslating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ZELENETZ, ANDREW D. · 2016 to 2020
$10.9MPersonalized Immunotherapy of Patients with Ovarian CancerP01CA190174 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SABBATINI, PAUL J, SPRIGGS, DAVID R · 2015 to 2019
$10.5MAdoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cellsR01CA138738 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BRENTJENS, RENIER JOSEPH · 2009 to 2013
$3.9MThe genomic pathogenesis of Follicular LymphomaR01CA190384 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MALEK, SAMI NIMER, WENDEL, HANS-GUIDO · 2015 to 2019
$2.7MTowards The Chemotherapy-Free Treatment of Follicular LymphomaR01CA183876 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WENDEL, HANS-GUIDO · 2014 to 2018
$2.5MExploring oncogenic translation programs in cancerR01CA207217 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WENDEL, HANS-GUIDO · 2016 to 2020
$2.1MThe contribution of protein translation to tumorigenesisR01CA142798 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WENDEL, HANS-GUIDO · 2010 to 2014
$1.9MP50 CA192937NCI NIH HHS P01 CA059350NCI NIH HHS P01 CA190174NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA138738NCI NIH HHS R01 CA142798NCI NIH HHS R01 CA183876NCI NIH HHS R01 CA190384NCI NIH HHS R01 CA207217NCRR NIH HHS P41 RR000862
Abstract
The HVEM (TNFRSF14) receptor gene is among the most frequently mutated genes in germinal center lymphomas. We report that loss of HVEM leads to cell-autonomous activation of B cell proliferation and drives the development of GC lymphomas in vivo. HVEM-deficient lymphoma B cells also induce a tumor-supportive microenvironment marked by exacerbated lymphoid stroma activation and increased recruitment of T follicular helper (T
Indexed as
Adoptive TransferAnimalsAntigens, CD19B-LymphocytesCell ProliferationHumansLymphocyte ActivationLymphoma, FollicularMiceNeoplasms, ExperimentalProtein DomainsProtein EngineeringReceptors, ImmunologicReceptors, Tumor Necrosis Factor, Member 14Recombinant Fusion ProteinsT-LymphocytesAntigens, CD19BTLA protein, humanReceptors, ImmunologicReceptors, Tumor Necrosis Factor, Member 14Recombinant Fusion ProteinsTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.